Regeneron and Sanofi’s Dupixent was approved in Canada for expanded use as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma.
The developer and distributor of pharmaceutical products said Monday the expanded approval follows the VOYAGE phase 3 trial of Dupixent, also known as dupilumab injection, and is used as an add-on maintenance treatment in patients with severe asthma with a type 2 inflammation phenotype.
Sanofi’s Dupixent was first approved in Canada in 2017 for the treatment of atopic dermatitis in adults, and has been since approved for adoslescents and children over the age of 6 or older with certain conditions.
is one of the most common long-term diseases of children, but adults can have asthma, too. Asthma causes wheezing, breathlessness, chest tightness, and coughing at night or early in the morning, according to the United States Centers for Disease Control and Prevention (CDC).
An asthma attack may include coughing, chest tightness, wheezing, and trouble breathing. The attack happens in your body’s airways, which are the paths that carry air to your lungs. As the air moves through your lungs, the airways become smaller, like the branches of a tree are smaller than the tree trunk. During an asthma attack, the sides of the airways in your lungs swell and the airways shrink. Less air gets in and out of your lungs, and mucous that your body makes clogs up the airways.
